Abbvie
Open
$222.51
Prev. Close
$222.29
High
$222.89
Low
$222.49
Market Snapshot
$393.36B
108.2
2.41
$56.33B
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 57,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
Rakuten Investment Management increased its stake in AbbVie to 232,464 shares, reflecting growing confidence in the company's performance and potential within the pharmaceutical industry.
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 57,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
Recently from Cashu
AbbVie Presents Promising Phase 3 CLL14 Trial Results for Chronic Lymphocytic Leukemia Treatment
AbbVie (Ticker: ABBV) continues to demonstrate its commitment to advancing cancer treatment with the recent presentation of the Phase 3 CLL14 trial data at the European Hematology Association (EHA) 20…
AbbVie Set to Present Key Blood Cancer Treatment Results at EHA 2026 Congress
AbbVie Inc (Ticker: ABBV) is poised to present vital new results from its blood cancer treatment portfolio at the upcoming European Hematology Association (EHA) Congress in 2026. The company plans to…
AbbVie's Elahere Approved for Ovarian Cancer, Revolutionizing Treatment Options in Oncology
AbbVie (Ticker: ABBV) makes a significant stride in oncology with its ovarian cancer drug Elahere gaining approval from the NHS in England for treating advanced, platinum-resistant ovarian cancer. Thi…
AbbVie Gains EU Approval for AQUIPTA, Advancing Migraine Treatment Options for Patients.
AbbVie (Ticker: ABBV) secures a pivotal regulatory victory with the recent approval of AQUIPTA (atogepant) by the European Commission for acute migraine treatment in adults. This significant achieveme…